Outlook Therapeutics Inc (OTLK)

$0.35 -0.05 (-11.55%)
Market Cap 32.87M
Revenue (ttm) 1.41M
Net Income (ttm) -62.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,426.95%
Debt to Equity Ratio -0.93
Volume 2,121,100
Avg Vol 2,398,924
Day's Range N/A - N/A
Shares Out 83.07M
Stochastic %K 7%
Beta -0.07
Analysts Sell
Price Target $5.30

Company Profile

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therap...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 619 3990
Address:
111 S. Wood Avenue, Unit #100, Iselin, United States
My_Lai_1968
My_Lai_1968 Mar. 19 at 6:25 AM
$OTLK The chart for OTLK is showing that both circular and triangular accumulation could begin within 48-72 hours due to an overhang of shares that are totally unaccounted for despite a modicum of retail buying that won't have the momentum to enable the stock price to continue in an uphill trajectory unless market manipulation occurs and forces both buyers and sellers to capitulate and decide to hold off on the stock until it settles and consolidates for 3-5 trading days before once again attempting to hit new highs due to an influx of share purchases which far exceed the downward pressure from shorting and that might constitute the appropriate time to take some profits before the next runup occurs as buyers look for equities and somewhat reasonable prices where consistent volume portends a favorable risk/reward scenario in the stock which would allow ample momentum to counterbalance the stochastics and rising wedge patterns to formulate exit paths for certain sellers and buyers.
1 · Reply
25_usa
25_usa Mar. 19 at 1:30 AM
$OTLK Insiders owning 31% currently which is awesome. Let’s hope for the best.
1 · Reply
AnalystLLM
AnalystLLM Mar. 19 at 12:55 AM
$OTLK a dilution is mainly from no income and banker will not loan
1 · Reply
TheMagnificentFerengi
TheMagnificentFerengi Mar. 18 at 10:33 PM
$OTLK a bank loan isn’t diluted, your stock value is. You aren’t the bank. Their ROI is not the same time frame or conditions.
1 · Reply
AnalystLLM
AnalystLLM Mar. 18 at 9:54 PM
$OTLK a banker willing to loan the company it must read the future balance sheet before the loan approved
1 · Reply
25_usa
25_usa Mar. 18 at 9:14 PM
$OTLK Right now, OTLK is still in a binary regulatory phase, so buyers will wait. Buyers are waiting for FDA outcome (Type A meeting +confirmatory evidence).
1 · Reply
SilentJoker34
SilentJoker34 Mar. 18 at 9:07 PM
$OTLK Im chillin 😎 🤔🧐
2 · Reply
Mountain_Sand_000
Mountain_Sand_000 Mar. 18 at 9:02 PM
$OTLK next stop .36
0 · Reply
Mountain_Sand_000
Mountain_Sand_000 Mar. 18 at 8:28 PM
$OTLK where did our .40 go
1 · Reply
FrancX
FrancX Mar. 18 at 8:04 PM
$OTLK It's time to stop justifying all this... I'm long, but how could I say there's something positive or hope that future profits will be excellent? Do you realize it would take aggressive drug sales and rapid expansion to fix a situation like this? This company is broke, in debt, and if we're lucky, it'll have sold a few hundred vials in a year... how vindictive! They're squeezing us like lemons. And thank goodness that scammer Jhar was talking about avoiding shareholder dilution!
2 · Reply
Latest News on OTLK
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

Mar 16, 2026, 8:05 AM EDT - 2 days ago

Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Mar 5, 2026, 4:15 PM EST - 13 days ago

Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland

Feb 19, 2026, 9:00 AM EST - 27 days ago

Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland

Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Feb 17, 2026, 8:05 AM EST - 4 weeks ago

Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter

Feb 11, 2026, 8:45 AM EST - 5 weeks ago

Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter

Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

Jan 6, 2026, 8:35 AM EST - 2 months ago

Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

US FDA declines to approve Outlook Therapeutics' eye disease drug

Dec 31, 2025, 4:23 PM EST - 2 months ago

US FDA declines to approve Outlook Therapeutics' eye disease drug

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

Dec 31, 2025, 4:15 PM EST - 2 months ago

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

Third Time's The Charm: Outlook Therapeutics Lytenava Heads To FDA, Again

Dec 28, 2025, 8:08 PM EST - 2 months ago

Third Time's The Charm: Outlook Therapeutics Lytenava Heads To FDA, Again

Outlook Therapeutics Announces New Employment Inducement Grants

Dec 26, 2025, 5:00 PM EST - 2 months ago

Outlook Therapeutics Announces New Employment Inducement Grants

Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

Dec 19, 2025, 8:05 AM EST - 3 months ago

Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 9:05 AM EST - 4 months ago

Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Nov 13, 2025, 8:30 AM EST - 4 months ago

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010

Nov 3, 2025, 8:35 AM EST - 4 months ago

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010

Outlook Therapeutics Provides Update on Type A Meeting with FDA

Sep 29, 2025, 8:45 AM EDT - 6 months ago

Outlook Therapeutics Provides Update on Type A Meeting with FDA

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)

Sep 3, 2025, 8:35 AM EDT - 7 months ago

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)

Outlook Therapeutics Requests Type A Meeting with FDA

Sep 2, 2025, 8:35 AM EDT - 7 months ago

Outlook Therapeutics Requests Type A Meeting with FDA

Outlook Therapeutics plunges more than 52% after FDA rejects wet AMD drug

Aug 28, 2025, 11:51 AM EDT - 7 months ago

Outlook Therapeutics plunges more than 52% after FDA rejects wet AMD drug

FDA Rejects Outlook Therapeutics Eye Drug For Second Time

Aug 28, 2025, 11:15 AM EDT - 7 months ago

FDA Rejects Outlook Therapeutics Eye Drug For Second Time

US FDA declines to approve Outlook Therapeutics' drug for eye condition

Aug 28, 2025, 6:39 AM EDT - 7 months ago

US FDA declines to approve Outlook Therapeutics' drug for eye condition

Outlook Therapeutics: Why The Odds Point To A Favorable FDA Decision

Aug 24, 2025, 9:15 AM EDT - 7 months ago

Outlook Therapeutics: Why The Odds Point To A Favorable FDA Decision

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

Aug 14, 2025, 8:05 AM EDT - 7 months ago

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

Jul 24, 2025, 9:00 AM EDT - 8 months ago

Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

Outlook Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 8 months ago

Outlook Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

Jul 1, 2025, 8:05 AM EDT - 9 months ago

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

Jun 18, 2025, 9:05 AM EDT - 9 months ago

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Jun 10, 2025, 8:05 AM EDT - 10 months ago

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

Jun 2, 2025, 7:00 AM EDT - 10 months ago

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

May 23, 2025, 6:30 AM EDT - 10 months ago

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

May 22, 2025, 4:01 PM EDT - 10 months ago

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

May 15, 2025, 4:01 PM EDT - 10 months ago

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Apr 8, 2025, 8:45 AM EDT - 1 year ago

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Feb 28, 2025, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 1 year ago

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

Feb 14, 2025, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Feb 4, 2025, 9:05 AM EST - 1 year ago

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Jan 31, 2025, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Jan 23, 2025, 9:05 AM EST - 1 year ago

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 22, 2025, 9:05 AM EST - 1 year ago

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

Jan 16, 2025, 12:09 PM EST - 1 year ago

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

NVS

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Jan 16, 2025, 6:00 AM EST - 1 year ago

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Dec 27, 2024, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Outlook Therapeutics® Streamlines Operations

Dec 13, 2024, 4:30 PM EST - 1 year ago

Outlook Therapeutics® Streamlines Operations

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Dec 4, 2024, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Outlook Therapeutics® Announces Executive Leadership Transition

Dec 3, 2024, 4:30 PM EST - 1 year ago

Outlook Therapeutics® Announces Executive Leadership Transition

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?

Nov 27, 2024, 9:27 AM EST - 1 year ago

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?

Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

Nov 27, 2024, 6:50 AM EST - 1 year ago

Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

Nov 6, 2024, 8:05 AM EST - 1 year ago

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

My_Lai_1968
My_Lai_1968 Mar. 19 at 6:25 AM
$OTLK The chart for OTLK is showing that both circular and triangular accumulation could begin within 48-72 hours due to an overhang of shares that are totally unaccounted for despite a modicum of retail buying that won't have the momentum to enable the stock price to continue in an uphill trajectory unless market manipulation occurs and forces both buyers and sellers to capitulate and decide to hold off on the stock until it settles and consolidates for 3-5 trading days before once again attempting to hit new highs due to an influx of share purchases which far exceed the downward pressure from shorting and that might constitute the appropriate time to take some profits before the next runup occurs as buyers look for equities and somewhat reasonable prices where consistent volume portends a favorable risk/reward scenario in the stock which would allow ample momentum to counterbalance the stochastics and rising wedge patterns to formulate exit paths for certain sellers and buyers.
1 · Reply
25_usa
25_usa Mar. 19 at 1:30 AM
$OTLK Insiders owning 31% currently which is awesome. Let’s hope for the best.
1 · Reply
AnalystLLM
AnalystLLM Mar. 19 at 12:55 AM
$OTLK a dilution is mainly from no income and banker will not loan
1 · Reply
TheMagnificentFerengi
TheMagnificentFerengi Mar. 18 at 10:33 PM
$OTLK a bank loan isn’t diluted, your stock value is. You aren’t the bank. Their ROI is not the same time frame or conditions.
1 · Reply
AnalystLLM
AnalystLLM Mar. 18 at 9:54 PM
$OTLK a banker willing to loan the company it must read the future balance sheet before the loan approved
1 · Reply
25_usa
25_usa Mar. 18 at 9:14 PM
$OTLK Right now, OTLK is still in a binary regulatory phase, so buyers will wait. Buyers are waiting for FDA outcome (Type A meeting +confirmatory evidence).
1 · Reply
SilentJoker34
SilentJoker34 Mar. 18 at 9:07 PM
$OTLK Im chillin 😎 🤔🧐
2 · Reply
Mountain_Sand_000
Mountain_Sand_000 Mar. 18 at 9:02 PM
$OTLK next stop .36
0 · Reply
Mountain_Sand_000
Mountain_Sand_000 Mar. 18 at 8:28 PM
$OTLK where did our .40 go
1 · Reply
FrancX
FrancX Mar. 18 at 8:04 PM
$OTLK It's time to stop justifying all this... I'm long, but how could I say there's something positive or hope that future profits will be excellent? Do you realize it would take aggressive drug sales and rapid expansion to fix a situation like this? This company is broke, in debt, and if we're lucky, it'll have sold a few hundred vials in a year... how vindictive! They're squeezing us like lemons. And thank goodness that scammer Jhar was talking about avoiding shareholder dilution!
2 · Reply
Alder77
Alder77 Mar. 18 at 7:43 PM
$OTLK It's called dilution. There's no stop loss. Let's stop writing bullshit and justifying the unjustifiable. They're printing shares without any belief and have no plan. Since they know, the revenue will suck. But what do you expect from a bunch of incompetents who submit the same thing three times and always get the same result: a failure
0 · Reply
Pharoh42
Pharoh42 Mar. 18 at 7:33 PM
$OTLK 2026 the shittiest investment year by far I lost all my profits from the past 12 years I only have my original money and still dropping This is ridiculous
1 · Reply
Britbox
Britbox Mar. 18 at 7:32 PM
$OTLK a lot of volume coming in at these levels, wonder if peoples stop losses are getting hit 
0 · Reply
The_Scientist
The_Scientist Mar. 18 at 7:18 PM
$OTLK I am so gonna penny flip this one. Fuck this management, liers and total imbeciles all of them.
1 · Reply
Glorioso2022
Glorioso2022 Mar. 18 at 7:03 PM
$OTLK uauuu.... good...good.... soon ZERO 👌👌👌👌👌
0 · Reply
Alder77
Alder77 Mar. 18 at 6:19 PM
$OTLK A relentless spiral of dilution. A company without alternatives and without a credible business. Incompetent management. I'm surprised by those who continue to be bullish.
0 · Reply
SilentJoker34
SilentJoker34 Mar. 18 at 5:14 PM
$OTLK Time will tell...🎆✨️
1 · Reply
BADBOYROY
BADBOYROY Mar. 18 at 4:08 PM
$OTLK probably the best post on this ticker. The BOD and the management team have nothing to lose. They are spending your money not theirs.
0 · Reply
The_Scientist
The_Scientist Mar. 18 at 3:36 PM
$OTLK I wonder how this company still burns so much cash? Like what the hell are they doing so innovative or outstanding? I am sure paying themselves big fat paychecks on our expense is a majority of this cash burn 🙄
6 · Reply
AnalystLLM
AnalystLLM Mar. 18 at 3:26 PM
$OTLK Jan 2026 data, you should publish too.
1 · Reply
adayxs
adayxs Mar. 18 at 3:07 PM
$OTLK Yup, still here watching paint dry. LOLOL.
1 · Reply
BADBOYROY
BADBOYROY Mar. 18 at 3:00 PM
$OTLK I want to pose a few questions to those who believe OTLK will avoid RS. What is the monthly cash burn for the company? How many shots would you need to sell to cover that amount? If you get FDA approval, how long would it take to ramp up sales in the US? I think these are fair questions. Sta I would love your opinion as you seem to be very good with numbers. Many of your posts involve data crunching and analysis. BobMark, you are a business owner. I would love your input as well. I believe they will eventually atain FDA approval. I just don’t think they have enough time for that to happen and ramp up us sales to avoid RS. Bulls, you have the floor.
2 · Reply